<DOC>
	<DOCNO>NCT00768989</DOCNO>
	<brief_summary>The purpose study determine combination atazanavir raltegravir take together safe effective treatment human immunodeficiency virus ( HIV ) .</brief_summary>
	<brief_title>Phase IIB Pilot Atazanavir + Raltegravir</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Human Immunodeficiency Virus ( HIV ) 1 positive status HIV ribonucleic acid ( RNA ) level &gt; =5000 copies/mL Antiretroviral treatmentnaive Absolute Cluster Differentiation 4 ( CD4 ) cell count meet 1 follow criterion : &lt; 350 cells/mm^3 Screening CD4 &gt; =350 &lt; =500 cells/mm^3 ONLY least 1 follow condition apply : Screening HIV RNA level &gt; 100,000 copies/mL , CD4 decline &gt; 50100 cells/mm^3/year , Age &gt; =55 year Any CD4 cell count , participant history acquire immune deficiency syndromedefining illness Medically stable Screening HIV genotype show resistance component study regimen ( Atazanavir , Raltegravir , Tenofovir/Emtricitabine ) Hepatitis B hepatitis C coinfection History current cardiac disease Electrocardiogram finding : PR Interval &gt; 260 msec ( severe 1st degree atrioventricular block ) QRS Interval &gt; 120 msec</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Combination Therapy</keyword>
</DOC>